Table 1.
Clinicopathologic features of all study participants with solitary huge hepatocellular carcinoma (≥ 10 cm) receiving hepatic resection or transarterial chemoembolization n (%)
| Variable | HR (n = 180) | TACE (n = 67) | Standardized difference, % | P-value |
| Age, yr | 46.3 ± 11.9 | 48.1 ± 12.4 | 14.2 | 0.307 |
| M/F | 158 (87.8)/22 (12.2) | 64 (95.5)/3 (4.5) | 37.2 | 0.073 |
| Tumor size, cm | 11.3 ± 2.2 | 11.9 ± 2.2 | 26.7 | 0.059 |
| HBsAg (+) | 153 (85) | 65 (97.0) | 70.1 | 0.009 |
| Child-Pugh class | ||||
| A | 175 | 64 | 8.2 | 0.790 |
| B | 5 | 3 | ||
| Cirrhosis | 133 (73.9) | 57 (85.1) | 31.2 | 0.064 |
| AFP | ||||
| ≥ 400 ng/mL | 75 (41.7) | 37 (55.2) | 27.1 | 0.057 |
| ≤ 400 ng/mL | 105 (58.3) | 30 (44.8) | ||
| Total bilirubin, μmol/L | 13.4 ± 5.9 | 16.1 ± 8.4 | 37.6 | 0.004 |
| ALT, U/L | 50.7 ± 52.4 | 63.6 ± 44.5 | 29.1 | 0.074 |
| AST, U/L | 60.6 ± 40.9 | 56.0 ± 35.4 | 13.0 | 0.418 |
| Prothrombin time, s | 12.8 ± 1.4 | 13.1 ± 2.3 | 9.7 | 0.355 |
| Albumin, g/L | 39.4 ± 4.6 | 37.5 ± 6.5 | 29.0 | 0.012 |
| Platelet count, 109/L | 210.0 ± 77.6 | 213.4 ± 89.4 | 3.8 | 0.771 |
| Vascular invasion | 26 (14.4) | 6 (9.0) | 19.1 | 0.253 |
Values with ‘‘±’’ are written as mean ± SD or number (%) of patients. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein; HR: Hepatic resection; TACE: Transarterial chemoembolization.